Pharmaceutical assessment screening factors | Number (%) |
---|---|
N | 35 |
Organ dysfunction | |
Kidney | 8 (23) |
Liver | 1 (3) |
Heart | 0 (0) |
Lung | 0 (0) |
Bone marrow | 0 (0) |
Brain | 0 (0) |
Dysfunction of more than one organ | 0 (0) |
Drugs requiring therapeutic monitoring | |
Glycopeptide antibiotic | 1 (3) |
Aminoglycosides | 4 (11) |
Theophylline/aminophylline | 3 (9) |
Digoxin | 1 (3) |
Carbamazepine | 0 (0) |
Lithium | 0 (0) |
Ciclosporin | 0 (0) |
Amphotericin B | 0 (0) |
Triazole antifungals | 0 (0) |
Number of drugs requiring therapeutic monitoring | |
0 | 28 (80) |
1 | 5 (14) |
2 | 2 (6) |
Other high-risk medications | |
Anticoagulation | 5 (14) |
Insulin | 8 (23) |
Opiates | 6 (17) |
Chemotherapy | 0 (0) |
Antiretrovirals | 0 (0) |
Clozapine | 0 (0) |
Number of high-risk medications* | |
0 | 18 (51) |
1 | 8 (23) |
2 | 7 (20) |
3 | 2 (6) |
ICU step-down patient | 1 (3) |
Patient with an infectious disease consult | 0 (0) |
Patient with cystic fibrosis | 5 (14) |
Organ transplant patient | 0 (0) |
Home intravenous therapy | 0 (0) |
Out-of-hospital respiratory service | 0 (0) |
Patient with HIV | 0 (0) |
Patient with Parkinson's disease on apomorphine | 0 (0) |
High-cost medication (not within NHS tariff) | 0 (0) |
Outside competency of attending pharmacist† | 0 (0) |
Pharmacist-documented PAL | |
1 | 4 (11) |
2 | 25 (71) |
3 | 6 (17) |
Expected PAL | |
1 | 11 (31) |
2 | 15 (43) |
3 | 9 (26) |
Measured agreement of PAL‡ | |
−2 | 0 (0) |
−1 | 6 (17) |
0 | 20 (57) |
+1 | 8 (23) |
+2 | 1 (3) |
*Number of high-risk medications includes drugs requiring therapeutic monitoring plus other high-risk medications.
†Outside competency refers to documentation by a junior pharmacist that the patient’s complexity is outside the scope of their competency.
‡Measured agreement of PALs is the difference of pharmacist-documented PAL minus the expected PAL with a range of values from −2 to +2.
ICU, intensive care unit; NHS, National Health Service; PAL, patient acuity level.